ReviewBreast cancer research and treatment2022
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
Review in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 77 citations in OpenAlex.
- Susan G. Komen's ShareForCures: a patient-engaged, nationwide breast cancer research registry.Journal of the National Cancer Institute · 2026Article
- A Clinically Aligned 18-Item Instrument for Measuring Inflammatory Breast Cancer Knowledge.JAMA network open · 2026Article
- Reprogramming the Immune Landscape of Inflammatory Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A Novel Patient-Derived Xenograft Model of Inflammatory Breast Cancer.Research square · 2026Article
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.JAMA network open · 2026Article
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.Breast care (Basel, Switzerland) · 2026Review
- Single-cell and spatial transcriptome profiling identifies cellular heterogeneity and immunosuppressive tumor microenvironment in inflammatory breast cancer.Journal of advanced research · 2026Article
- Article
- Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.Breast cancer research and treatment · 2026Article
- Breast Cancer Cell-Derived Exosomal miR-92b-3p Promotes Tumor Angiogenesis and Metastasis by Suppressing PTEN in Vascular Endothelial Cells.Oncology research · 2026Article
- Rare overlap of subtype and phenotype: HER2-positive pleomorphic invasive lobular carcinoma presenting with an inflammatory breast cancer phenotype: a case report and targeted treatment strategy.Frontiers in oncology · 2026Article
- Pathological complete response to neoadjuvant TACHP in HER2-positive/HR-positive inflammatory breast cancer: a case report.Frontiers in oncology · 2026Article
- Article
- The Gems and Pitfalls of Inflammatory Breast Disease: An Illustrated Review of Mastitis. What the Radiologist Should Know.Radiology research and practice · 2026Review
- Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database.Breast cancer research and treatment · 2025Article
- The E2F1/SBK1 axis activates the Notch signaling pathway to accelerate the malignant progression of breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Trends in Surgical Treatment for cT4 Breast Cancer After Neoadjuvant Systemic Therapy: A Nationwide Study in The Netherlands.Annals of surgical oncology · 2025Article
- Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.Journal of the National Cancer Institute · 2025Article
- Clinical Significance and Prognostic Value of TLR4 and AGER in Inflammatory Breast Cancer.Cancers · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInflammatory breast cancer is a deadly and aggressive type of breast cancer. A key challenge relates to the need for a more detailed, formal, objective definition of IBC, the lack of which compromises clinical care, hampers the conduct of clinical trials, and hinders the search for IBC-specific biomarkers and treatments because of the heterogeneity of patients considered to have IBC.
methodsSusan G. Komen, the Inflammatory Breast Cancer Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to review the state of IBC and to propose initiatives to advance the field. After literature review of the defining clinical, pathologic, and imaging characteristics of IBC, the experts developed a novel quantitative scoring system for diagnosis.
resultsThe experts identified through consensus several "defining characteristics" of IBC, including factors related to timing of onset and specific symptoms. These reflect common pathophysiologic changes, sometimes detectable on biopsy in the form of dermal lymphovascular tumor emboli and often reflected in imaging findings. Based on the importance and extent of these characteristics, the experts developed a scoring scale that yields a continuous score from 0 to 48 and proposed cut-points for categorization that can be tested in subsequent validation studies.
conclusionTo move beyond subjective 'clinical diagnosis' of IBC, we propose a quantitative scoring system to define IBC, based on clinical, pathologic, and imaging features. This system is intended to predict outcome and biology, guide treatment decisions and inclusion in clinical trials, and increase diagnostic accuracy to aid basic research; future validation studies are necessary to evaluate its performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.